- Home
- Latest news
Latest news
Could we be on our way to eliminating cancer for good?
What once seemed like an unattainable goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision to create a world without cancer.
Johnson & Johnson named to Fortune‘s 2025 America’s Most Innovative Companies list
The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.
More from Johnson & Johnson
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers
Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.
Careers
Looking for a career opportunity at Johnson & Johnson? Search our available jobs.
What is wAIHA?
Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and a potential targeted treatment developed by Johnson & Johnson that’s currently in clinical trials.
“The surgical devices I design help speed healing and save lives”
Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
Press releases
New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation
Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison
Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1 Phase 2 CAPTIVATE long-term follow-up data further supports sustained efficacy and safety profile of fixed-duration ibrutinib plus venetoclax treatment in patients receiving frontline treatment for chronic lymphocytic leukaemia2
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24 Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis
Johnson & Johnson Launches the ETHICON™ 4000 Stapler for Elevated Surgical Experience and the Most Secure Staple Line Yet1
The stapling system features ETHICON™ 3D Reloads with proprietary 3D Stapling Technology and enhanced Gripping Surface Technology to manage tissue complexities and reduced potential leaks and bleeds at the staple line2I New ETHICON advanced stapling technology to be harnessed for future use exclusively on the OTTAVA™ Robotic Surgical System ETHICON 4000 Stapler and ETHICON™ 3D Reloads will be showcased at the American Society for Metabolic and Bariatric Surgery Annual Meeting on June 15-19, 2025
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO® in transplant-ineligible newly diagnosed patients
